Asia Pacific Point of Care TB And Drug-Resistant TB Testing Market Size, Share, Competitive Landscape and Trend Analysis Report, By Testing Technology, By Type of TB, By Treatment Type, By End-User, By Region, And Segment Forecasts, 2024 - 2031
- Published Date : 2024-09-26
- Pages : 100
- Report Id : 40474
- Categories : Healthcare
This report describes the global market size of Point of Care TB And Drug-Resistant TB Testing Market from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 11.2% from 2024 to 2031.
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Point of Care TB And Drug-Resistant TB Testing Market estimated at US $77.3 Billion in the year 2022, is projected to reach a revised size of US $ 1,67.15 Billion by 2031, growing at a CAGR of 11.2% during the forecast period 2024-2031.
The Point of Care (POC) TB and Drug-Resistant TB Testing Market refers to the segment of healthcare focused on diagnostic solutions that allow for rapid and accurate tuberculosis (TB) detection, including drug-resistant strains, at or near the patient site. These tests offer a significant advantage over traditional lab-based methods by providing faster results, often within hours, enabling immediate treatment decisions. POC testing is crucial in combating TB, especially in low-resource settings, as it reduces diagnostic delays, helps curb transmission, and supports better patient outcomes. This market includes a variety of diagnostic tools such as molecular tests, immunoassays, and nucleic acid amplification tests (NAATs), which are used to identify both TB and its resistant forms like multi-drug resistant (MDR) and extensively drug-resistant (XDR) TB. With increasing global TB incidence and rising drug resistance, the demand for POC TB tests is growing, particularly in regions with high disease burden. Key stakeholders in this market include diagnostic device manufacturers, healthcare providers, governments, and NGOs working to address the global TB epidemic.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Point of Care TB And Drug-Resistant TB Testing Market as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Testing Technology
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Nucleic Acid Amplification Tests (NAATs)
Gene Sequencing
Immunoassays
Enzyme-Linked Immunosorbent Assays (ELISA)
Lateral Flow Tests
Microscopy-Based Tests
Fluorescence Microscopy
Culture-Based Tests
Liquid Culture Systems
Solid Culture Systems
The Point of Care TB and Drug-Resistant TB Testing Market can be categorized by testing technology into four main segments. Molecular diagnostics play a critical role, with Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) being widely used for rapid TB detection by amplifying the DNA of the tuberculosis bacteria. Gene sequencing further allows for the identification of drug-resistant strains. Immunoassays, such as Enzyme-Linked Immunosorbent Assays (ELISA) and Lateral Flow Tests, detect TB antigens or antibodies, providing cost-effective diagnostic solutions, particularly in low-resource settings. Microscopy-based tests, like Fluorescence Microscopy, remain traditional methods of detecting TB by visually identifying the bacteria in sputum samples, offering simplicity and reliability. Lastly, Culture-based tests are considered the gold standard, where liquid culture systems provide faster results compared to solid culture systems but both allow for the growth and identification of TB bacteria, as well as determining drug susceptibility. Each of these technologies serves a critical function in diagnosing TB and drug-resistant strains, depending on the resources available and the clinical setting.
By Type of TB
Drug-Sensitive TB
Drug-Resistant TB
Multidrug-Resistant TB (MDR-TB)
Extensively Drug-Resistant TB (XDR-TB)
Pre-Extensively Drug-Resistant TB (Pre-XDR-TB)
The Point of Care TB and Drug-Resistant TB Testing Market is segmented by the type of tuberculosis (TB) being diagnosed, primarily divided into Drug-Sensitive TB and Drug-Resistant TB. Drug-Sensitive TB refers to strains of TB that respond effectively to standard first-line anti-TB drugs, making it easier to treat with available therapies. However, Drug-Resistant TB poses a significant global health challenge due to its resistance to these common treatments. Within drug-resistant TB, the most concerning is Multidrug-Resistant TB (MDR-TB), which resists at least isoniazid and rifampicin, two of the most powerful first-line drugs. Worse yet, Extensively Drug-Resistant TB (XDR-TB) is resistant not only to these drugs but also to fluoroquinolones and at least one second-line injectable drug, making it much harder to treat. Another emerging threat is Pre-Extensively Drug-Resistant TB (Pre-XDR-TB), which is resistant to rifampicin and fluoroquinolones but not yet fully resistant to second-line injectable drugs, representing an intermediate stage between MDR-TB and XDR-TB. Early detection of these types through point-of-care testing is critical for proper treatment and controlling the spread of resistant TB strains.
By Treatment Type
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
The Point of Care TB and Drug-Resistant TB Testing Market can also be categorized based on the type of treatment into First-Line Anti-TB Drugs and Second-Line Anti-TB Drugs. First-line drugs are the initial treatment options used to combat drug-sensitive TB and include medications like isoniazid, rifampicin, pyrazinamide, and ethambutol. These drugs are highly effective for most TB cases when administered properly, typically over a 6-month course, and are the backbone of TB control programs worldwide. When TB becomes resistant to these first-line drugs, particularly in cases of Multidrug-Resistant TB (MDR-TB), Second-line anti-TB drugs are required. These drugs include fluoroquinolones (like levofloxacin and moxifloxacin) and injectable agents such as amikacin or kanamycin. These treatments are more complex, toxic, expensive, and take longer, often up to 20-24 months, compared to first-line therapy. The need for precise point-of-care testing becomes critical in distinguishing between drug-sensitive and drug-resistant TB, as misdiagnosis or delayed diagnosis can result in ineffective treatment, further spread of the disease, and increased mortality. Early detection through these tests ensures appropriate therapy, whether first-line or second-line drugs, can be started immediately to improve patient outcomes.
By End-User
Hospitals
Clinics
Diagnostic Laboratories
Public Health Centers
Home Care Settings
Mobile Health Units
The Point of Care TB and Drug-Resistant TB Testing Market is also segmented by end-users, which include Hospitals, Clinics, Diagnostic Laboratories, Public Health Centers, Home Care Settings, and Mobile Health Units. Hospitals serve as primary centers for advanced TB diagnostics and treatment, especially for severe or complicated cases like drug-resistant TB, where comprehensive testing and monitoring are required. Clinics provide more localized care, often in communities with high TB prevalence, making them essential for rapid testing and initiating treatment protocols. Diagnostic laboratories are critical for performing detailed TB tests, including molecular diagnostics, culture-based methods, and drug susceptibility tests. These labs often collaborate with hospitals and clinics to ensure accurate diagnoses, especially for drug-resistant strains. Public health centers, often government-run, are key players in national TB control programs, offering TB screening and treatment services, particularly in underserved regions. Home care settings are becoming increasingly important as POC TB testing technology advances, allowing for patient-friendly, at-home diagnostics and monitoring, which can reduce the burden on healthcare facilities. Mobile health units bring essential TB testing services to remote or hard-to-reach areas, helping improve access to diagnosis and treatment, especially in regions with limited healthcare infrastructure. Each of these end-users plays a vital role in improving TB detection, treatment, and overall disease management.
Company-
Cepheid. Cepheid
Thermo Fisher Scientific Inc
Abbott
BD
Siemens Healthineers AG
Mylab Discovery Solutions Pvt. Ltd.
BIOM RIEUX
Qiagen
Lucira Health
Hoffmann-La Roche Ltd
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
TABLE OF CONTENTS
Market Taxonomy
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis and Recommendations
1.3. RA Analysis and Recommendations
2. Market Introduction
2.1. Market Definition
3. Market Background
3.1. Parent/Associated Market Overview
3.1.1.Point of Care TB And Drug-Resistant TB Testing Outlook
3.1.2.Point of Care TB And Drug-Resistant TB Testing Overview
3.2. Effect of Covid-19 Impact
3.3. Macro-Economic Overview
3.3.1. GDP Growth
3.3.2. Retail Industry Growth
3.4. Pricing Analysis
3.5. Challenges related to adoption of Point of Care TB And Drug-Resistant TB Testing
3.6. Regulations of Point of Care TB And Drug-Resistant TB Testing
3.7. Forecast Factors: Relevance and Impact
3.8. Market Dynamics
3.8.1. Drivers
3.8.2. Restraints
3.8.3. Opportunity
3.8.4. Trends
3.8.5. SWOT Analysis
4. Market Forecast
4.1. Market Value Projections
4.2. Market Size Projections
4.3. Y-o-Y Projections
4.4. Absolute Opportunity Analysis
5. Global Point of Care TB And Drug-Resistant TB Testing Value Chain Analysis
5.1.Point of Care TB And Drug-Resistant TB Testing Value Chain
5.1.1. List of Raw Type of TB Suppliers
5.1.2. List of Point of Care TB And Drug-Resistant TB Testing Manufacturer
5.1.3. List of Segment
6. Global Point of Care TB And Drug-Resistant TB Testing Analysis by Type
6.1. Introduction
6.1.1. Market Value Share Analysis By Type
6.1.2. Y-o-Y Growth Analysis By Type
6.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Type
6.3. Market Attractiveness Analysis by Type
7. GlobalPoint of Care TB And Drug-Resistant TB Testing Analysis By Type of TB
7.1. Introduction
7.1.1. Market Value Share Analysis By Type of TB
7.1.2. Y-o-Y Growth Analysis By Type of TB
7.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Type of TB
7.3. Market Attractiveness Analysis By Type of TB
8. Market Structure Analysis
8.1. Market Analysis by Tier of Companies
8.1.1. By Large, Medium, and Small
8.2. Market Concentration
8.2.1. By Top 5 and by Top 10
8.3. Type ion Capacity Share Analysis
8.3.1. By Large, Medium, and Small
8.3.2. By Top 5 and Top 10
8.4. Type Roadmap
9. Competition Analysis
9.1. Competition Dashboard
9.2. Company Profiles (15 Companies)
9.2.1.Cepheid. Cepheid
9.2.1.1. Overview
9.2.1.2. Type Portfolio
9.2.1.3. Financial Overview
9.2.2. Thermo Fisher Scientific Inc
9.2.2.1. Overview
9.2.2.2. Type Portfolio
9.2.2.3. Financial Overview
9.2.3. Abbott
9.2.3.1. Overview
9.2.3.2. Type Portfolio
9.2.3.3. Financial Overview
9.2.4. BD
9.2.4.1. Overview
9.2.4.2. Type Portfolio
9.2.4.3. Financial Overview
9.2.5. Siemens Healthineers AG
9.2.5.1. Overview
9.2.5.2. Type Portfolio
9.2.5.3. Financial Overview
9.2.6.Mylab Discovery Solutions Pvt. Ltd.
9.2.6.1. Overview
9.2.6.2. Type Portfolio
9.2.6.3. Financial Overview
9.2.7.BIOMÉRIEUX
9.2.7.1. Overview
9.2.7.2. Type Portfolio
9.2.7.3. Financial Overview
9.2.8.Qiagen
9.2.8.1. Overview
9.2.8.2. Type Portfolio
9.2.8.3. Financial Overview
9.2.9. MedMira
9.2.9.1. Overview
9.2.9.2. Type Portfolio
9.2.9.3. Financial Overview
9.2.10.Pace Hoffmann-La Roche Ltd
9.2.10.1. Overview
9.2.10.2. Type Portfolio
9.2.10.3. Financial Overview
9.2.11.COMPANY 11
9.2.11.1. Overview
9.2.11.2. Type Portfolio
9.2.11.3. Financial Overview
9.2.12. COMPANY 12
9.2.12.1. Overview
9.2.12.2. Type Portfolio
9.2.12.3. Financial Overview
9.2.13. COMPANY 13
9.2.13.1. Overview
9.2.13.2. Type Portfolio
9.2.13.3. Financial Overview
9.2.14. COMPANY 14
9.2.14.1. Overview
9.2.14.2. Type Portfolio
9.2.14.3. Financial Overview
9.2.15. COMPANY 15
9.2.15.1. Overview
9.2.15.2. Type Portfolio
9.2.15.3. Financial Overview
10. Global Point of Care TB And Drug-Resistant TB Testing Analysis By Region
10.1. Introduction
10.1.1. Market Value Share Analysis By Region
10.1.2. Y-o-Y Growth Analysis By Region
10.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Region
10.2.1. North America
10.2.2. Middle East and Africa
10.2.3. South America
10.2.4. Asia-Pacific
10.2.5. Others
10.3. Current Market Size (USD Mn) Forecast 2023-2030 By Region
10.3.1. North America
10.3.2. Middle East and Africa
10.3.3. South America
10.3.4. Asia-Pacific
10.3.5. Others
10.4. Market Attractiveness Analysis By Region
11. North America Point of Care TB And Drug-Resistant TB Testing Analysis
11.1. Introduction
11.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
11.2.1. U.S.
11.2.2. Canada
11.2.3. Mexico
11.2.4. Rest of North America
11.3. Current Market Size (USD Mn) Forecast 2023-2030 By Country
11.3.1. U.S.
11.3.2. Canada
11.3.3. Mexico
11.3.4. Rest of North America
11.4. Historical Market Size (USD Mn) Analysis 2018-2022 By Type
11.5. Current Market Size (USD Mn) Forecast 2023-2030 By Type
11.6. Historical Market Size (USD Mn) Analysis 2018-2022 By Type of TB
11.7. Current Market Size (USD Mn) Forecast 2023-2030 By Type of TB
12. South America Point of Care TB And Drug-Resistant TB Testing Analysis
12.1. Introduction
12.2. Regional Pricing Analysis
12.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
12.3.1. Brazil
12.3.2. Argentina
12.3.3. Rest of South America
12.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of South America
12.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Type
12.6. Current Market Size (USD Mn) Forecast 2023-2030 By Type
12.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Type of TB
12.8. Current Market Size (USD Mn) Forecast 2023-2030 By Type of TB
13. Europe Point of Care TB And Drug-Resistant TB Testing Analysis
13.1. Introduction
13.2. Regional Pricing Analysis
13.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
13.3.1. Germany
13.3.2. Italy
13.3.3. France
13.3.4. Spain
13.3.5. U.K.
13.3.6. Rest of Europe
13.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
13.4.1. Germany
13.4.2. Italy
13.4.3. France
13.4.4. Spain
13.4.5. U.K.
13.4.6. Rest of Europe
13.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Type
13.6. Current Market Size (USD Mn) Forecast 2023-2030 By Type
13.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Type of TB
13.8. Current Market Size (USD Mn) Forecast 2023-2030 By Type of TB
14. Middle East and Africa Point of Care TB And Drug-Resistant TB Testing Analysis
14.1. Introduction
14.2. Regional Pricing Analysis
14.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
14.3.1. Saudi Arabia
14.3.2. U.A.E.
14.3.3. South Africa
14.3.4. Turkey
14.3.5. Rest of Middle East and Africa
14.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
14.4.1. Saudi Arabia
14.4.2. U.A.E.
14.4.3. South Africa
14.4.4. Turkey
14.4.5. Rest of Middle East and Africa
15. Asia-Pacific Point of Care TB And Drug-Resistant TB Testing Analysis
15.1. Introduction
15.2. Regional Pricing Analysis
15.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
15.3.1. China
15.3.2. India
15.3.3. Japan
15.3.4. South Korea
15.3.5. Singapore
15.3.6. Australia and New Zealand
15.3.7. Rest of Asia-Pacific
15.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
15.4.1. China
15.4.2. India
15.4.3. Japan
15.4.4. South Korea
15.4.5. Singapore
15.4.6. Australia and New Zealand
15.4.7. Rest of Asia-Pacific
i. Research Methodology
ii. Assumptions & Acronyms
LIST OF FIGURES
Figure 01: Global Point of Care TB And Drug-Resistant TB Testing, BPS Analysis,By Type, 2018(H), 2023(E) & 2030(F)
Figure 02: Global Point of Care TB And Drug-Resistant TB Testing, Y-O-Y Growth,By Type, 2020(A) - 2030(F)
Figure 03: Global Point of Care TB And Drug-Resistant TB Testing Attractiveness Analysis,By Type (2020)
Figure 04: Global Point of Care TB And Drug-Resistant TB Testing, BPS Analysis, By Type of TB, 2018(H), 2023(E) & 2030(F)
Figure 05: Global Point of Care TB And Drug-Resistant TB Testing, Y-O-Y Growth, By Type of TB, 2018(H) - 2030(F)
Figure 06: Global Point of Care TB And Drug-Resistant TB Testing Attractiveness Analysis, By Type of TB
Figure 07: Global Point of Care TB And Drug-Resistant TB Testing, Value Analysis,By Type, 2018(H)-2030(F)
Figure 08: Global Point of Care TB And Drug-Resistant TB Testing, Value Analysis, by Type of TB , 2018(H)-2030(F)
Figure 09: Global Point of Care TB And Drug-Resistant TB Testing, BPS Analysis, by Region, 2018(H), 2023(E) & 2030(F)
Figure 10: Global Point of Care TB And Drug-Resistant TB Testing, Y-O-Y Growth, by Region, 2018(H) - 2030(F)
Figure 11: Global Point of Care TB And Drug-Resistant TB Testing Attractiveness Analysis, by Region
Figure 12: North America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn Forecast, 2018 – 2022
Figure 13: North America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn Forecast, 2023 – 2030
Figure 14: South America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, 2018 – 2022
Figure 15: South America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, 2023 – 2030
Figure 16: Europe Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, 2018 – 2022
Figure 17: Europe Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, 2023 – 2030
Figure 18: Middle East and Africa Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, 2018 – 2022
LIST OF TABLES
Table 01: Global Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type, 2018(H) – 2030(F)
Table 02: Global Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB, 2018(H) – 2030(F)
Table 03: Global Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 04: North America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 05: North America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast,By Type, 2018(H) – 2030(F)
Table 06: North America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB, 2018(H) – 2030(F)
Table 07: South America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 08: South America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast,By Type, 2018(H) – 2030(F)
Table 09: South America Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB, 2018(H) – 2030(F)
Table 10: Europe Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) and Forecast, by Country, 2018(H) – 2030(F)
Table 11: Europe Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type, 2018(H) – 2030(F)
Table 12: Europe Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB EndUser, 2018(H) – 2030(F)
Table 13: Middle East and Africa Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 14: Middle East and Africa Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type, 2018(H) – 2030(F)
Table 15: Middle East and Africa Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB, 2018(H) – 2030(F)
Table 16: Asia-Pacific Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 17: Asia-Pacific Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type, 2018(H) – 2030(F)
Table 18: Asia-Pacific Point of Care TB And Drug-Resistant TB Testing Value (USD Mn) Forecast, By Type of TB, 2018(H) – 2030(F)
Direct Purchase
Your perfect start with Stats And ResearchWant to customize this report?
This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Avail PDF Sample Reports
You may also be lnterested in..
Stats And Research ™ Copyright © 2024 .